Alzamend Neuro, Inc. (NASDAQ:ALZN) Major Shareholder Purchases $21,250.00 in Stock

Alzamend Neuro, Inc. (NASDAQ:ALZNGet Rating) major shareholder Milton C. Ault III acquired 25,000 shares of the business’s stock in a transaction that occurred on Thursday, May 12th. The shares were acquired at an average cost of $0.85 per share, with a total value of $21,250.00. Following the transaction, the insider now directly owns 9,791,667 shares in the company, valued at approximately $8,322,916.95. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

ALZN traded up $0.06 on Friday, hitting $0.94. 1,262,215 shares of the stock traded hands, compared to its average volume of 1,530,244. Alzamend Neuro, Inc. has a 52 week low of $0.80 and a 52 week high of $33.55. The business has a fifty day moving average price of $1.06 and a two-hundred day moving average price of $1.61.

Alzamend Neuro (NASDAQ:ALZNGet Rating) last released its quarterly earnings data on Tuesday, March 15th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.01). Equities research analysts expect that Alzamend Neuro, Inc. will post -0.12 EPS for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Schonfeld Strategic Advisors LLC acquired a new position in Alzamend Neuro during the 3rd quarter worth $97,000. Warberg Asset Management LLC acquired a new position in shares of Alzamend Neuro in the 3rd quarter valued at $43,000. Sassicaia Capital Advisers LLC acquired a new stake in Alzamend Neuro during the 3rd quarter worth $289,000. Marshall Wace LLP acquired a new stake in Alzamend Neuro during the 4th quarter worth $313,000. Finally, Cubist Systematic Strategies LLC raised its stake in Alzamend Neuro by 97.1% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 46,669 shares of the company’s stock worth $144,000 after buying an additional 22,997 shares during the period. Institutional investors and hedge funds own 0.95% of the company’s stock.

Alzamend Neuro Company Profile (Get Rating)

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's.

Recommended Stories

Insider Buying and Selling by Quarter for Alzamend Neuro (NASDAQ:ALZN)

Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.